Wound Management Technologies, Inc. Announces FDA Clearan...( FORT WORTH Texas Nov. 13 /- Wound...),Health

FORT WORTH, Texas, Nov. 13 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today the 510k clearance of a new wound management product utilizing their patented hydrolyzed collagen technology.

The new addition to our product line (patent pending) combines hydrolyzed collagen with the healing properties of polysulfated glycosaminoglycan (PSGAG) and will initially be available in gel form. PSGAG enhances the absorptive capacity of the hydrolyzed collagen gel, making it appropriate for the management of exudative wounds. In addition, PSGAG has been shown to prepare the granulation tissue for epidermal migration by maintaining a uniform, low density granulation tissue more easily modified by the migrating epithelium thus improving the rate of epithelialization of a chronic wound and reducing scarring.

The product has been cleared and is indicated for topical use in the management of chronic and acute wounds and dermal ulcers including the management of:
-- Pressure Ulcers (Stages I-IV)

-- Venous Stasis Ulcers

-- Diabetic Ulcers

-- First and Second Degree Burns

-- Surgical Wounds

-- Traumatic wounds

-- Superficial Wounds

-- Ulcers resulting from arterial insufficiency

-- Grafted wounds and donor sites

"We are delighted with the FDA clearance of the hydrolyzed collagen with polysulfated glycosaminoglycan (PSGAG)," states Cathy Bradshaw, President of Wound Care Innovations. "This allows us to bring to the high margin, advanced wound care market, a product that utilizes our proven, patented hydrolyzed collagen and incorporates the distinctive characteristics of PSGAG to prepare the wound bed for re-epithelialization, wound closure."

Costs associated with wound care are significant, exceeding billions of dollars annually. "We are introducing a new, improved product which addresses the epi
'/>"/>